NCT03646188 2026-04-16
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
Phase 1 Terminated
SkinJect, Inc.
Regeneron Pharmaceuticals
Sol-Gel Technologies, Ltd.
University of Arizona
Stanford University
Hoffmann-La Roche
Novartis